Compounds to induce endogenous oligodendrocyte progenitor cells to remyelinate axons in MS patients

Progentos Therapeutics is focused on developing innovative regenerative medicines aimed at treating multiple sclerosis (MS) by harnessing the body's natural repair mechanisms. The company is working on first-in-class small-molecule therapeutics designed to activate oligodendrocyte progenitor cells, which are crucial for the regeneration of myelin—the protective sheath that insulates nerve fibers. By targeting these progenitor cells, Progentos aims to stimulate the formation of new oligodendrocytes, thereby facilitating the remyelination of neurons that have been damaged by MS. This approach addresses a significant unmet need in the treatment of MS, as existing therapies primarily focus on slowing disease progression rather than repairing the damage already incurred.

The research conducted by Progentos has led to the identification and validation of a novel target that shows promise for effective remyelination in pre-clinical studies. The compounds developed by the company are intended to not only prevent further decline in neurological function but also potentially restore lost capabilities in patients suffering from MS. By advancing this regenerative medicine, Progentos Therapeutics aims to improve the quality of life for individuals affected by this debilitating condition, marking a significant step forward in the treatment landscape for multiple sclerosis.

United States

Progentos Therapeutics is a biotech company focused on developing treatments for multiple sclerosis and other neuropsychiatric disorders. The company has raised $65 million in Series A financing and will have operations in Watertown, MA, USA and Naarden, The Netherlands.

Progentos Therapeutics

Company Details